In this article, we will be taking a look at the 11 best future stocks to buy now.
Over the past year, investors have poured money into cutting-edge technologies like artificial intelligence and electric cars. These patterns have made some wonder if regulators will curb their expansion in 2025 or if the government will give them more leeway. Bradley Tusk, a venture capitalist, spoke on CNBC about the industries that are predicted to grow in 2025 and how legislative changes may impact investments in these booming sectors.
We would probably see a more hospitable environment for M&A activity and new technology in fintech, healthcare tech, and energy, he said, even though some of the regulations on big tech might remain in place. As a result, the different elements are lining up nicely, particularly in the venture capital industry. Although there hasn’t been much activity there in recent years, things are finally beginning to improve.
Tusk expressed concerns over the government’s ability to ensure safety and competitiveness in tech, citing Internet 2.0 as an example of delayed regulation. He warned that without strong federal leadership, states might adopt conflicting AI regulations, making compliance difficult for companies.
Despite this, Tusk believes the AI industry will push forward due to heavy investment and ongoing momentum. However, he emphasized that 2025 must be the year AI delivers real-world results—moving beyond hype to generate actual revenue and savings.
Tusk believes the future of crypto looks brighter, expecting more favorable and reasonable regulations under the current administration compared to the past four years under SEC Chair Gary Gensler, who was strongly anti-crypto. While not all legislation will be welcomed, it’s likely to be more balanced.
On fintech, Tusk noted the previous administration was heavy-handed with regulations. There’s hope for significant administrative deregulation, but he’s doubtful it will happen if it requires new legislation.
Stocks
Our Methodology
For our methodology, we selected the stocks based on their high upside potential and ranked them according to hedge fund sentiment data from Q1 2025, as tracked by the Insider Monkey database.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
Here is our list of the 11 best future stocks to buy now.
11. ImmunityBio, Inc. (NASDAQ:IBRX)
Number of Hedge Fund Holders: 10
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best future stocks to buy now. It is transforming cancer care through immunotherapies that activate the body’s natural defenses. Its lead therapy, ANKTIVA (nogapendekin alfa inbakicept), has already been approved by the FDA for treating certain types of bladder cancer. The company is now expanding its approach with a focus on reversing lymphopenia, an immune deficiency often caused by chemotherapy, radiation, or immunotherapy.
In June 2025, the FDA authorized an Expanded Access Program for ANKTIVA under the Cancer BioShield platform, making it the first approved therapy to target treatment-induced lymphopenia in patients with solid tumors who failed standard therapies. At ASCO 2025, data showed that restoring immune health with ANKTIVA, especially when paired with CAR-NK therapy, can significantly improve survival in metastatic pancreatic cancer patients.
Internationally, ImmunityBio, Inc. (NASDAQ:IBRX) is gaining momentum. In July 2025, the UK approved ANKTIVA with BCG for non-muscle invasive bladder cancer (NMIBC), marking its first approval outside the U.S. Additionally, a partnership with Saudi Arabia’s health system will bring the Cancer BioShield platform to the Middle East.
The company is also expanding clinical trials, including a U.S.-based study testing ANKTIVA with PD-1 inhibitors in non-small cell lung cancer (NSCLC), with plans to expand globally. Meanwhile, the business is seeking broader FDA approval for ANKTIVA + BCG in bladder cancer after addressing regulatory hurdles.
By targeting immune collapse caused by cancer treatments, ImmunityBio, Inc. (NASDAQ:IBRX) is introducing a paradigm shift, fighting both cancer and immune dysfunction simultaneously. With FDA designations, strategic global alliances, and promising clinical data, the company is advancing a potentially life-extending new standard in oncology.
10. Cosan S.A. (NYSE:CSAN)
Number of Hedge Fund Holders: 13
Cosan S.A. (NYSE:CSAN), a Brazilian conglomerate founded in 1936, operates across energy, agribusiness, logistics, oil and gas, and natural gas distribution. Through key subsidiaries like Raízen (bioenergy), Rumo (rail logistics), Compass (natural gas), and Moove (lubricants), the business plays a central role in Brazil’s energy transition by connecting agricultural production to export hubs and investing in cleaner fuels.
In 2025, Cosan S.A. (NYSE:CSAN) strengthened its leadership in regional energy with a landmark move: its subsidiary Edge completed Brazil’s first import of Argentine natural gas via Bolivia. This initiative enhances supply flexibility and promotes energy integration in South America, aligning with Brazil’s cleaner energy goals.
The company also focused on portfolio optimization by divesting non-core assets, including its stake in Vale, while acquiring DIPI Holdings S.A. to boost its logistics platform. A major corporate restructuring streamlined operations and improved investor transparency.
Operationally, Cosan S.A. (NYSE:CSAN) faced a fire at its Moove lubricants plant in Rio de Janeiro. Thanks to an agile, asset-light approach and insurance coverage for repairs, disruptions were minimized, preserving financial stability.
The company continues to invest in sustainable growth. Its joint venture, Raízen, is expanding renewable fuel production, and Rumo is developing efficient agri-export corridors. These efforts reflect Cosan S.A. (NYSE:CSAN)’s broader commitment to decarbonization and energy resilience.
9. BRF S.A. (NYSE:BRFS)
Number of Hedge Fund Holders: 16
BRF S.A. (NYSE:BRFS), a major global food company headquartered in Brazil, has significantly advanced its international strategy in 2025 through two key developments: a transformative merger with Marfrig Global Foods and major expansions in Saudi Arabia and China.
On May 15, 2025, BRF S.A. (NYSE:BRFS) and Marfrig announced a definitive merger to form MBRF Global Foods Company S.A., aiming to become a global protein industry leader. The merger, pending shareholder approval on August 5, is expected to deliver R$805 million (approx. $141 million) in annual synergies through cost optimization and operational integration. The new entity is also exploring redomiciliation and a potential U.S. listing to enhance valuation and liquidity, positioning it among the best growth stocks in the sector.
Simultaneously, the corporation is expanding its international presence. In Saudi Arabia, it began constructing a $160 million processed-foods facility in Jeddah, its third plant in the country and seventh in the Middle East. Set to open in 2026 with a 40,000-tonne annual capacity, the factory supports Saudi food security goals and strengthens BRF S.A. (NYSE:BRFS)’s position in the halal market.
In China, the company completed the acquisition of a processed-foods plant in Henan Province, doubling its production capacity in the region to 60,000 tonnes. This move enables BRF S.A. (NYSE:BRFS) to better serve local consumers and reduce exposure to global supply chain disruptions.
